Defunct Company
Total Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
1,783
NCT00979251
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2009
Completion: Aug 31, 2011
NCT01397422
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Phase: Phase 2/3
Start: Jul 31, 2011
Completion: Oct 31, 2013
NCT02136914
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Phase: Phase 3
Start: May 31, 2014
Completion: Dec 31, 2015
NCT02153632
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
Start: Jul 30, 2014
Completion: May 20, 2016
NCT02202551
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Start: Jul 31, 2014
Completion: Feb 28, 2018
NCT02153645
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
Start: Aug 18, 2014
NCT02274766
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Start: Oct 31, 2014
Completion: Mar 10, 2016
NCT02471222
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Start: May 31, 2015
Completion: Jun 30, 2016
NCT03436199
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Start: Mar 29, 2018
Completion: Dec 10, 2019
NCT03567057
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Start: Jul 18, 2018
Completion: Apr 18, 2021
NCT04387773
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Phase: Phase 4
Role: Collaborator
Start: Nov 5, 2020
Completion: Sep 30, 2022